Evommune (EVMN) announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $27.88. Evommune anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any transaction-related expenses. Morgan Stanley & Co. LLC, Leerink Partners LLC, Evercore ISI, Cantor Fitzgerald & Co., and William Blair & Company, L.L.C. acted as placement agents for the private placement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVMN:
- Evommune price target raised to $55 from $40 at Evercore ISI
- Evommune: Robust IL-18 Phase 2a Atopic Dermatitis Data Underpins Buy Rating and Higher $55 Target with Additional Indication Upside
- Evommune price target raised to $65 from $35 at H.C. Wainwright
- Midday Fly By: Coca-Cola reports Q4 beat, BP suspends buyback
- Evommune Advances EVO301 After Positive Phase 2a Results